Biostem Technologies Net Income
| BSEM Stock | USD 5.80 0.28 5.07% |
As of the 14th of February 2026, Biostem Technologies shows the Downside Deviation of 7.2, mean deviation of 7.37, and Risk Adjusted Performance of 0.0746. Biostem Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Biostem Technologies, which can be compared to its peers. Please confirm Biostem Technologies jensen alpha, as well as the relationship between the potential upside and skewness to decide if Biostem Technologies is priced correctly, providing market reflects its regular price of 5.8 per share. Given that Biostem Technologies has jensen alpha of 0.7783, we suggest you to validate Biostem Technologies's prevailing market performance to make sure the company can sustain itself at a future point.
Biostem Technologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biostem Technologies' valuation are provided below:Biostem Technologies does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Biostem |
Biostem Technologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biostem Technologies' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biostem Technologies.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Biostem Technologies on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Biostem Technologies or generate 0.0% return on investment in Biostem Technologies over 90 days. Biostem Technologies is related to or competes with Satellos Bioscience, Imugene, Zivo Bioscience, and Vicapsys Life. BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutica... More
Biostem Technologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biostem Technologies' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biostem Technologies upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.2 | |||
| Information Ratio | 0.074 | |||
| Maximum Drawdown | 48.13 | |||
| Value At Risk | (12.42) | |||
| Potential Upside | 21.04 |
Biostem Technologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biostem Technologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biostem Technologies' standard deviation. In reality, there are many statistical measures that can use Biostem Technologies historical prices to predict the future Biostem Technologies' volatility.| Risk Adjusted Performance | 0.0746 | |||
| Jensen Alpha | 0.7783 | |||
| Total Risk Alpha | 0.0575 | |||
| Sortino Ratio | 0.1013 | |||
| Treynor Ratio | 4.33 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biostem Technologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biostem Technologies February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0746 | |||
| Market Risk Adjusted Performance | 4.34 | |||
| Mean Deviation | 7.37 | |||
| Semi Deviation | 6.59 | |||
| Downside Deviation | 7.2 | |||
| Coefficient Of Variation | 1232.63 | |||
| Standard Deviation | 9.85 | |||
| Variance | 97.06 | |||
| Information Ratio | 0.074 | |||
| Jensen Alpha | 0.7783 | |||
| Total Risk Alpha | 0.0575 | |||
| Sortino Ratio | 0.1013 | |||
| Treynor Ratio | 4.33 | |||
| Maximum Drawdown | 48.13 | |||
| Value At Risk | (12.42) | |||
| Potential Upside | 21.04 | |||
| Downside Variance | 51.82 | |||
| Semi Variance | 43.46 | |||
| Expected Short fall | (9.14) | |||
| Skewness | 1.14 | |||
| Kurtosis | 1.63 |
Biostem Technologies Backtested Returns
Biostem Technologies is very risky given 3 months investment horizon. Biostem Technologies secures Sharpe Ratio (or Efficiency) of 0.14, which signifies that the company had a 0.14 % return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.35% are justified by taking the suggested risk. Use Biostem Technologies Mean Deviation of 7.37, risk adjusted performance of 0.0746, and Downside Deviation of 7.2 to evaluate company specific risk that cannot be diversified away. Biostem Technologies holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.18, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biostem Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Biostem Technologies is expected to be smaller as well. Use Biostem Technologies sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Biostem Technologies.
Auto-correlation | 0.17 |
Very weak predictability
Biostem Technologies has very weak predictability. Overlapping area represents the amount of predictability between Biostem Technologies time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biostem Technologies price movement. The serial correlation of 0.17 indicates that over 17.0% of current Biostem Technologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 1.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Biostem Technologies reported net income of (2.39 Million). This is 100.7% lower than that of the Healthcare sector and 103.41% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.42% higher than that of the company.
Biostem Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostem Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostem Technologies could also be used in its relative valuation, which is a method of valuing Biostem Technologies by comparing valuation metrics of similar companies.Biostem Technologies is currently under evaluation in net income category among its peers.
Biostem Fundamentals
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 | |||
| Operating Margin | (18.22) % | |||
| Current Valuation | 37.89 M | |||
| Shares Outstanding | 9.24 M | |||
| Price To Earning | (0.49) X | |||
| Price To Sales | 151.81 X | |||
| Revenue | 2.52 M | |||
| Gross Profit | 163.78 K | |||
| EBITDA | (1.59 M) | |||
| Net Income | (2.39 M) | |||
| Cash And Equivalents | 1.37 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 1.32 M | |||
| Current Ratio | 0.26 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (581.57 K) | |||
| Earnings Per Share | (0.58) X | |||
| Target Price | 6.3 | |||
| Number Of Employees | 13 | |||
| Beta | 1.56 | |||
| Market Capitalization | 34.19 M | |||
| Total Asset | 2.67 M | |||
| Retained Earnings | (5.31 M) | |||
| Working Capital | (1.55 M) | |||
| Current Asset | 307 K | |||
| Current Liabilities | 1.86 M | |||
| Z Score | 13.6 | |||
| Net Asset | 2.67 M |
About Biostem Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostem Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostem Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostem Technologies based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.